ViGenCell’s Immune Cell Therapies To Get A Boost From $85M IPO

IPO Priced At Top Of Stock Price Band

 
• By Jung Won Shin

Korean bioventure ViGenCell successfully completes an IPO on the Kosdaq market with strong subscription rates from investors, reflecting the continued keen interest in biopharma shares in South Korea this year.

human cells and veins
ViGenCell Developing Both Autologous And Universal Cell Therapies • Source: Alamy

More from South Korea

More from Focus On Asia